Wednesday, November 20, 2019
Print Current Session:
|
|
Wednesday
SESSION 25:
NEW DEVELOPMENTS IN LOWER EXTREMITY RELATED TOPICS: DOWNSIDE OF DCBs: THE PACLITAXEL COATED DEVICES INCREASE MORTALITY ISSUE
|
|
SESSION 25 SCHEDULE | |
9:10 AM - 9:15 AM | Introductory Remarks And Overview |
Presenter(s):Gary M. Ansel, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:16 AM - 9:21 AM | The Downsides To DCBs: Cost; Distal Embolization; Increased Mortality: Are They Substantive |
Presenter(s):Andrew Holden, MBChB Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:22 AM - 9:27 AM | Update On The Meta-Analysis Showing An Increased Mortality In Patients Treated With Drug (Paclitaxel) Coated Lower Extremity Devices (DCBs And DESs): What Is The Current Interpretation |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:28 AM - 9:33 AM | Understanding The Pharmacology, Mechanisms Of Action And Toxicity Of Paclitaxel On Drug Coated Devices: How Could Paclitaxel Influence Mortality |
Presenter(s):Juan F. Granada, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:34 AM - 9:39 AM | Is The Increased Mortality Risk Of Paclitaxel Coated Lower Extremity Devices Observed In The Meta-Analysis Real And Meaningful: Update From The VIVA Leaders Analysis: Currently How Should It Influence Use Of These Devices: Where Is This Issue Going |
Presenter(s):Peter A. Schneider, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:40 AM - 9:45 AM | Current Status Of The Discussion On Paclitaxel Coated Lower Extremity Devices And Their Impact On Patient Mortality: Another View And Where Does The FDA Stand And Why |
Presenter(s):Michael R. Jaff, DO Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:46 AM - 9:51 AM | What Is The Society for Vascular Surgery (SVS) Doing About This Issue And Where Does It Stand On It |
Presenter(s):Kim J. Hodgson, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:52 AM - 9:57 AM | What Is The Response To And Position Of An Industry Partner (Medtronic) Which Is Vested In Drug Eluting Technology |
Presenter(s):Mark Pacyna Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:58 AM - 10:03 AM | Update On The Late Results (> 5 Years) Of The Zilver PTX DES Trials That Are Relevant To This Issue: Including The Corrected Late Patient Mortality Data |
Presenter(s):Michael D. Dake, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
10:04 AM - 10:09 AM | Long-Term Safety And Effectiveness Of Paclitaxel Coated Devices Versus Non-Coated Devices For Fempop Occlusive Lesions: From Japanese RCTs And Registries: How Do These Data Bear On The Paclitaxel-Mortality Issue |
Presenter(s):Osamu Iida, MD / Hiroyoshi Yokoi, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
10:10 AM - 10:15 AM | 6-Year Comparison Of Mortality And Its Causes In 1500 Patients Treated With Paclitaxel Coated DCBs Or DESs Versus Bare Metal Stents (BMSs) Or Plain Old Balloon Angioplasty (POBA) |
Presenter(s):Francesco Liistro, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
10:16 AM - 10:19 AM | Large Population Based Multicenter German Study Indicates Paclitaxel Coated Devices May Be Associated With Lower Late Mortality Than Uncoated Devices In Some Patient Subgroups |
Presenter(s):Christian A. Behrendt, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
10:19 AM - 10:25 AM | Panel Discussion |
END OF SESSION 25 | |
previous | next |